Treatment FailureHeart FailureTreatment OutcomeAntimalarialsDrug ResistanceDrug CombinationsPyrimethamineDrug Therapy, CombinationSulfadoxineMalaria, FalciparumRetrospective StudiesTime FactorsAnti-Bacterial AgentsRecurrenceChloroquineFollow-Up StudiesArtemisininsSubstance Abuse Treatment CentersProspective StudiesPlasmodium falciparumHIV InfectionsAtovaquoneAmodiaquineDrug Administration ScheduleFluorenesProguanilAntiprotozoal AgentsKidney Failure, ChronicDrug Resistance, ViralAnti-HIV AgentsFailure to ThriveSurvival AnalysisAntitubercular AgentsPrognosisDihydropteroate SynthaseParasitic Sensitivity TestsRisk FactorsCefiximeLiver Failure, AcuteCohort StudiesMicrobial Sensitivity TestsAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsDrug MonitoringCombined Modality TherapyDoxorubicinMetronidazolePenicillin G ProcaineDouble-Blind MethodAmoxicillinSurvival RateParasitemiaViral LoadEthanolaminesPatient ComplianceDose-Response Relationship, DrugDisease-Free SurvivalLiver FailureDrug Resistance, BacterialPredictive Value of TestsGonorrheaGenotypeMelarsoprolDrug Resistance, NeoplasmAzithromycinFluoxymesteroneAntiretroviral Therapy, Highly ActiveSeverity of Illness IndexAnti-Infective AgentsAnticonvulsantsMutationRandomized Controlled Trials as TopicAcute DiseaseDisease ProgressionKaplan-Meier EstimateMultiple Organ FailureClinical Trials as TopicVincristineAdministration, OralChronic DiseaseCyclophosphamideSalvage TherapyHodgkin DiseaseUgandaTrypanosoma brucei gambienseSubstance-Related DisordersHIV-1CeftriaxoneMycoplasma genitaliumEtoposideTetrahydrofolate DehydrogenaseDisease Models, AnimalPolymerase Chain ReactionDrug Resistance, MultipleRifampinCisplatinAnti-Retroviral AgentsAntimonyEquipment FailureSesquiterpenes